Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2017 Oct 4;16(12):2747–2758. doi: 10.1158/1535-7163.MCT-17-0717

Figure 3.

Figure 3

Oral administration of DMAPT (100mg/kg, M-F/week) modulates body composition and functional performance in PyMT+ mice. A) DMAPT restores grip strength. B) DMAPT partially ameliorates tumor-induced decline in rotarod performance. C) DMAPT treatment does not alter tumor-induced loss of fat. D) DMAPT has minimal effect on tumor-induced changes in body lean mass. E) DMAPT reduces percentage of body free water. F) DMAPT does not significantly change total body water ratio. g) DMAPT slows down body weight gain. * indicates significance between experimental groups and wild type group, p<0.05. # indicates significance between PyMT+ group with vehicle and with DMAPT treatments at same age-testing point, p<0.05. n= 10 mice/group.